Brian Hill, MD, PhD, Cleveland Clinic

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.